{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:39:52Z","timestamp":1790912392583,"version":"4.1.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To understand changes in the underlying progression of early Parkinson's disease, it is important to derive estimates of the threshold for meaningful motor progression on the MDS-UPDRS Part III in OFF medication state.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To estimate this threshold using two approaches: anchor-based analyses, and clinical consensus via a modified Delphi panel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For the anchor-based analyses, data from a Phase II clinical trial were used. Mean and median MDS-UPDRS Part III change scores were calculated for those participants rated as \u2018Minimally worse\u2019 on the Clinical Global Impression of Improvement (using the first visit rated as \u2018Minimally worse\u2019 or worse, and at Weeks 24 and 52). Cumulative data up to Week 104 were used to assess the difference between motor progressors\u2019 and non-progressors\u2019 change scores on motor-related outcomes. For the modified Delphi panel, a panel of 13 expert clinicians received an online survey in two rounds and provided responses anonymously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For the anchor-based analyses, estimates of meaningful change ranged from 4\u22126 points. Numerically worse change scores were identified on motor-related outcomes for participants who had experienced motor progression compared with those who had not. For the modified Delphi panel, consensus was reached in Round 2, with 92% agreeing that 5 points is suitable to define a clinically meaningful motor progression threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results of the anchor-based analyses and modified Delphi panel were consistent, supporting a meaningful motor progression threshold of a worsening of 5 points on the MDS-UPDRS Part III (OFF medication state) in an early Parkinson's disease population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x241302337","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T21:33:59Z","timestamp":1736890439000},"page":"97-110","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III"],"prefix":"10.1177","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3542-8181","authenticated-orcid":false,"given":"Dylan","family":"Trundell","sequence":"first","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan W.","family":"Davies","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-4412","authenticated-orcid":false,"given":"Louise","family":"Barrett","sequence":"additional","affiliation":[{"name":"Modus Outcomes, Cheltenham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4071-0886","authenticated-orcid":false,"given":"Stefano","family":"Zanigni","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Shariati","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0140-7820","authenticated-orcid":false,"given":"Rebecca","family":"Rogers","sequence":"additional","affiliation":[{"name":"Modus Outcomes, Cheltenham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Monnet","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Moore","sequence":"additional","affiliation":[{"name":"Roche Products Ltd, Welwyn Garden City, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Pross","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Pagano","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland"},{"name":"University of Exeter Medical School, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9390-273X","authenticated-orcid":false,"given":"Stefan","family":"Cano","sequence":"additional","affiliation":[{"name":"Modus Outcomes, Cheltenham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7610-4700","authenticated-orcid":false,"given":"Tania","family":"Nikolcheva","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.59.12.1937"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.2.393"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22060"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12553"},{"key":"e_1_3_4_8_2","article-title":"Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS part III","volume":"37","author":"Zanigni S","year":"2022","unstructured":"Zanigni S, Shariati N, Simuni T, et al. Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS part III. Mov Disord 2022; 37: S361\u2013S362.","journal-title":"Mov Disord"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.10.006"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2648.1994.tb01207.x"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/ACM.0000000000001812"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20050134"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3310\/hta2030"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202867"},{"key":"e_1_3_4_16_2","unstructured":"Linstone HA Turoff M. The Delphi method: techniques and applications http:\/\/www.foresight.pl\/assets\/downloads\/publications\/Turoff_Linstone.pdf (2002 accessed 12 December 2024)."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1502165"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pri.35"},{"key":"e_1_3_4_19_2","first-page":"152","volume-title":"Third symposium on Parkinson's disease","author":"Schwab RS","year":"1969","unstructured":"Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Danoldson IML (eds) Third symposium on Parkinson's disease. Edinburgh: Churchill Livingstone, 1969, pp.152\u2013157."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02260863"},{"key":"e_1_3_4_21_2","unstructured":"US Food and Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making https:\/\/www.fda.gov\/media\/166830\/download (2023 accessed 12 December 2024)."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1616-3"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.012"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-022-03286-w"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-021-02925-y"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014485627744"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-120028508"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23638"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.295"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20914"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12632"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/467131"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.846126"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d556"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X241302337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X241302337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X241302337","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:50:56Z","timestamp":1777589456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X241302337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1177\/1877718X241302337"],"URL":"https:\/\/doi.org\/10.1177\/1877718x241302337","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}